Mabpharm Limited (HKG:2181)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
Pharmaceuticals	646.10M	258.23M	87.16M	55.92M	82.88M
Pharmaceuticals Growth	150.20%	196.27%	55.87%	-32.53%	-
Total	646.10M	258.23M	87.16M	55.92M	82.88M
Total Growth	150.20%	196.27%	55.87%	-32.53%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
PRC	646.10M	258.23M	87.16M	55.92M	82.88M
PRC Growth	150.20%	196.27%	55.87%	-32.53%	-
Total	646.10M	258.23M	87.16M	55.92M	82.88M
Total Growth	150.20%	196.27%	55.87%	-32.53%	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 7, 2026

Data Sources Report a data error